Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2

Phase 1 Completed 22 enrolled Sanofi Profil GmbH, Neuss, Germany · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

The objective of this study is to test whether Lixisenatide (AVE0010) restores first phase and improves second phase insulin response in subjects with diabetes mellitus type 2.

Timeline

Start: 2009-06
Primary completion: 2009-08
Completion: 2009-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lixisenatide	Peptide	20 ug	Subcutaneous

Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2

Summary

Timeline

Drugs

Indications